Amphastar Pharmaceuticals AMPH Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments

Gain Loss On Interest Rate Derivative Instruments Not Designated As Hedging Instruments at other companies

POS

Post HoldingsPOST

$2.4M—

TFX

TeleflexTFX

$8.31M+95.9%

LBR

LB Pharmaceuticals Inc Common StockLBRX

$200K-74.0%

Great Southern BancorpGSBC

-$2K+91.7%

Red Rock Resorts, Inc.RRR

-$966K-119%

TFX

TeleflexTFX

$0-100%

Other financials

Income statement

See full

Revenue$171.2M+0.4%

Gross profit$70.3M-17.5%

Operating income$13.6M-63.5%

Net income$6.4M-74.6%

EPS (diluted)$0.14-72.5%

Balance sheet

See full

Cash & equivalents$170.9M-6.5%

Total debt$686.6M+5.2%

Total equity$445.5M—

Total assets$1.6B+1.3%

Cash flow

See full

Operating cash flow$47.8M+36.4%

CapEx$9.5M-11.1%

Free cash flow$38.3M+57.2%

Valuation

See full

Market cap$927.72M-19.9%

Enterprise value$1.44B-11.3%

P/E11.7×+3.5×

P/S1.3×-0.3×

Profitability

See full

Gross margin47.3%-3.2pp

Operating margin16.2%-10.4pp

Net margin11%-8.4pp

FCF margin18.8%-1.8pp

Returns & leverage

See full

Return on equity14.7%—

Debt / equity0.2×—

Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's gain loss on interest rate derivative instruments not designated as hedging instruments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Amphastar Pharmaceuticals's gain loss on interest rate derivative instruments not designated as hedging instruments?: Amphastar Pharmaceuticals (AMPH) reported gain loss on interest rate derivative instruments not designated as hedging instruments of $416K in Q1 2026.
How has Amphastar Pharmaceuticals's gain loss on interest rate derivative instruments not designated as hedging instruments changed year-over-year?: Amphastar Pharmaceuticals's gain loss on interest rate derivative instruments not designated as hedging instruments increased by 119.4% year-over-year, from -$2.14M to $416K.